Last updated on April 2015

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma


Brief description of study

This randomised, controlled, multicentre trial is designed to assess the efficacy and safety of sequential icotinib plus chemotherapy versus single icotinib as first-line treatment in stage IIIB/IV lung adenocarcinoma patients with EGFR mutation.

Clinical Study Identifier: NCT02103257

Find a site near you

Start Over
Sorry. There are no research sites conducting this study in the radius provided. ( View all Sites )
If you would like to be informed of other studies that may be of interest to you, you may sign up for CenterWatch.com's Patient Notification Service. ( Sign Up )